However, HDAC inhibitors currently in use for cancer treatments are nonselective and target multiple HDACs, resulting in unwanted side effects, such as ventricular arrhythmia, thrombocytopenia or fatigue. Here, HDAC9 is linked to Thrombocytopenia.